rly-4008
relay therapeutics
['rly-4008', 'fgfr2 inhibitor']
just published: rly-4008, the first highly selective #fgfr2 inhibitor with activity across fgfr2 alterations and resistance mutations by , vaibhav sahai, jessica casaletto, and colleagues. #asco23
Follow Cancer Discovery for high-impact articles and news covering major advances in basic, translational, and clinical cancer research. Published by @AACR.